University of Padua at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Padua brings 5 presentations to ESGCT 2026 in Hamburg. Its groups work on gene therapy for GM1 gangliosidosis and other neurodegenerative conditions, including patient-derived organoids with engineered microglia and a hyperactive human beta-galactosidase. Related work covers lipid nanoparticle editing of blood stem cells and CAR T cells aimed at pancreatic tumours.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Padua Padua, Italy | |
Poster Wed Oct 28 1:30pm–3:30pm Patient-Derived Organoids Integrated with HSPC-Derived Microglia for Preclinical Evaluation of GM1 Gangliosidosis Gene Therapy Rare and inherited disease Poster Wed Oct 28 1:30pm–3:30pm TREM2 microglia engineering via HSC gene therapy – an innovative treatment approachfor neurodegenerative diseases characterized by microglial dysfunction Poster Thu Oct 29 2:00pm–4:00pm A Hyperactive Human Beta-Galactosidase for Gene Therapy of GM1 Gangliosidosis and Related Diseases Poster Thu Oct 29 2:00pm–4:00pm Profiling the TME remodeling upon ECM-targeting CAR-T cell therapy in PDAC Poster Thu Oct 29 2:00pm–4:00pm Rational lipid nanoparticle engineering enables therapeutic genome editing and functional enhancement of human Hematopoietic Stem Cells |
Instantly find 20 buyers from University of Padua
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction